Objective: Despite the critical importance of pathologically confirmed samples for biomarker validation, only a few studies have correlated CSF Ab42 values in vivo with postmortem Alzheimer's disease (AD) pathology, while none evaluated the CSF Ab42/Ab40 ratio. We compared CSF Ab42 and Ab42/Ab40 ratio as biomarkers predicting AD neuropathological changes in patients with a short interval between lumbar puncture and death. Methods: We measured CSF Ab40 and Ab42 and assessed AD pathology in 211 subjects with rapidly progressive dementia (RPD) and a definite postmortem diagnosis of CreutzfeldtJakob disease (n = 159), AD (n = 12), dementia with Lewy bodies (DLB, n = 4), AD/DLB mixed pathologies (n = 5), and various other pathologies (n = 31). Results: The score reflecting the severity of Ab pathology showed a better correlation with ln(Ab42/Ab40) (R 2 = 0.506, b = À0.713, P < 0.001) than with ln(Ab42) (R 2 = 0.206, b = À0.458, P < 0.001), which was confirmed after adjusting for covariates. Ab42/Ab40 ratio showed significantly higher accuracy than Ab42 in the distinction between cases with or without AD pathology (AUC 0.818 AE 0.028 vs. 0.643 AE 0.039), especially in patients with Ab42 levels ≤495 pg/mL (AUC 0.888 AE 0.032 vs. 0.518 AE 0.064). Using a cut-off value of 0.810, the analysis of Ab42/Ab40 ratio yielded 87.0% sensitivity, 88.2% specificity in the distinction between cases with an intermediate-high level of AD pathology and those with low level or no AD pathology. Interpretation: The present data support the use of CSF Ab42/Ab40 ratio as a biomarker of AD pathophysiology and noninvasive screener for Ab pathology burden, and its introduction in the research diagnostic criteria for AD.
Introduction
The pathological hallmarks of Alzheimer's disease (AD) include the extracellular deposition of protein amyloid beta (Ab) in brain parenchyma and blood vessel walls, and the intraneuronal accumulation of hyperphosphorylated tau (p-tau). 1 According to the prevailing amyloid hypothesis, aggregation and tissue deposition of Ab precede p-tau driven neurofibrillary degeneration and anticipate the clinical onset of the disease by several years. [2] [3] [4] Positron emission tomography (PET) with fibrillary Abspecific radiotracers and the cerebrospinal fluid (CSF) quantitative assay of the 42 amino acid form of Ab (Ab42) provide in vivo evidence of brain Ab deposition and are included in current research diagnostic criteria for AD. 5, 6 However, despite the analytical and clinical validation and the established inverse correlation with amyloid-related neuropathological changes, the detection of CSF Ab42 still suffers from limitations. 7, 8 Ab42 is highly labile and prone to aggregate, which makes its concentrations susceptible to variation in the preanalytical processing. [9] [10] [11] Furthermore, CSF Ab levels may vary significantly among individuals, leading to a misinterpretation of test results in the presence of constitutively high or low quantities of Ab42 relative to chosen diagnostic "cut-off values". These and perhaps other factors might also be responsible for the reported lack of optimal correlation between CSF Ab42 values and amyloid-PET 12 or neuropathological findings. 8, 13 To overcome these limits, several authors proposed to evaluate the ratio between Ab42 and the 40 amino acid form of Ab(Ab40) CSF concentrations instead of that of Ab42 alone. [14] [15] [16] [17] [18] Given that Ab40 is a more stable peptide which is not significantly decreased in AD, 19 it has been hypothesized that the CSF Ab42/Ab40 ratio may improve the diagnostic accuracy by allowing the normalization with respect to the sources of Ab42 level variability unrelated to the AD pathology burden. Increasing evidence supports, indeed, the better diagnostic performance of Ab42/Ab40 ratio in comparison to Ab42 alone. 15, 16, 20 Specifically, the Ab42/Ab40 ratio showed a better accordance with amyloid-PET findings 17, [21] [22] [23] [24] and an improved diagnostic accuracy also in a clinical setting when CSF biomarker assays gave discordant results. 18, 25, 26 However, to date, the relationship between antemortem CSF Ab42/Ab40 ratio with postmortem AD pathology has not been systematically studied. Aiming to contribute to the issue of the added diagnostic value of CSF Ab42/Ab40 ratio in the clinical setting, we tested the hypothesis that the CSF Ab42/Ab40 ratio better predicts the burden of AD-related neuropathological changes than CSF Ab42 alone. To this aim, we took advantage of a large series of neuropathologically verified cases of Creutzfeldt-Jakob disease (CJD) and other rapidly progressive dementias (RPDs), in which the CSF biomarker assessment was performed, on average, only a few months before death.
Methods

Patient selection
We studied patients affected by RPD referred for diagnosis to the Laboratory of Neuropathology (NP-Lab) at the Institute of Neurological Sciences of Bologna between January 2005 and December 2017. Inclusion criteria were limited to the availability of sufficient and qualitatively adequate postmortem brain tissue for AD neuropathological diagnosis and staging, and a CSF sample of sufficient volume to complete all assays and collected within 36 months from death. The screening of NP-Lab database yielded a total of 211 suitable cases (Fig. S1 ). Primary neuropathological diagnosis included CJD (n = 159), AD (n = 12), dementia with Lewy bodies (DLB, n = 4), AD/DLB mixed pathologies (n = 5), encephalitis (n = 7), vascular dementia (n = 6), primary central nervous system malignancy (n = 5), Wernicke's encephalopathy (n = 3), hypoxic encephalopathy (n = 2), progressive supranuclear palsy (n = 1), variably protease-sensitive prionopathy (n = 1), and progressive multifocal leukoencephalopathy (n = 1). Finally, in five cases, neuropathological investigations did not reveal a significant specific pathology to reach a definitive diagnosis. All subjects gave written informed consent for the use of their clinical data for research purposes and the study was approved by the local ethical review board.
Neuropathological examination
Neuropathological examination was performed using standardized procedures as described. 13 Briefly, tissues from the right hemisphere, brainstem, and cerebellum were rapidly frozen at À80°C, while the left parts of the brain were fixed in 10% formalin. Samples from the fixed hemisphere were taken from 23 brain regions, according to a standardized protocol. 27 Histopathological examination was performed on seven lm thick sections of formalin-fixed and paraffinembedded brain tissue blocks. All sections were stained hematoxylin-eosin for screening. Also, immunohistochemistry with antibodies specific for PrP (3F4, dilution 1:400, Signet Labs), hyperphosphorylated tau (AT8, dilution 1:100, Innogenetics), and Ab (4G8, dilution 1:5000, Signet Labs) were applied to all cases. To this aim, several brain regions were stained, mainly following established consensus criteria. the CERAD neuritic plaques score, 33 and classified each case according to the level of AD neuropathologic change (ABC score). 1 To obtain a more continuous measure of Ab brain load, we also calculated a score after evaluating semiquantitatively immunostained sections from the cerebral cortex (one from each lobe: frontal, temporal, parietal, and occipital), amygdala, hippocampus (CA1 region), striatum, midbrain, and cerebellum. Parenchymal Ab pathology (Fig. S2 ) was graded (0-6) as follows: 0-entirely negative; 2-rare or sparse deposits (2-4 plaques in at least one 1009 microscopic field); 4-moderate number of deposits (5-10 plaques); 6-multiple deposits, disseminate (>10 plaques). An additional point was added when core plaques were also noted. Cerebral amyloid angiopathy (CAA) (Fig. S2 ) was evaluated in leptomeninges and parenchyma as follows: 0-entirely negative; 1-up to two vessels focally involved; 3-more than half of the vessels involved; and 2-intermediate between 1 and 3. For each case, a cumulative Ab score (0-90) was calculated. Similarly, we formulated a score for AD-related tau neuropathological change by semiquantitative evaluation of p-tau immunoreactivity (0-no immunoreactivity; 1-mild; 2-moderate; 3-prominent) in six brain regions, namely transentorhinal cortex, entorhinal cortex, parahippocampal gyrus, middle temporal gyrus, middle frontal gyrus, and occipital cortex. Fine neuritic (threads) tau deposits, neurofibrillary tangles, and thick neuritis, which are part of neuritic plaques, were analyzed separately. Finally, a cumulative score (0-54) (AD tau score) was given.
CSF analysis
Antemortem CSF was obtained by lumbar puncture at the L3-L4 or L4-L5 interspinal space following a standard procedure, centrifuged at 1000g for 10 min when showing even mild signs of blood contamination, divided into aliquotes, and stored in polypropylene tubes at À80°C until analysis.
CSF Ab42, and Ab40 levels were analyzed using commercially available ELISA kits (INNOTEST Ab1-42, and INNOTEST Ab1-40; Innogenetics/Fujirebio) according to the manufacturer's instructions.
For the interpretation of Ab42 results, we used an inhouse cut-off value of Ab42 ≤ 495 pg/mL. The calculation of this cut-off and further details about the pre-and analytical variables are reported in supplementary methods in Appendix S1. The ratio of Ab42 to Ab40 was calculated according to a previously published formula [(Ab42)/(Ab40)910]. 15 
Statistical analysis
Statistical analysis was performed using SPSS Statistics version 21 (IBM, Armonk, NY, USA) and Stata SE version 14.2 (StataCorp LLC, Texas, USA). Depending on the data distribution, results were expressed as mean and standard deviation or median and interquartile range (IQR). Due to the non-normal distribution of biomarker values, Mann-Whitney U test and Kruskal-Wallis test were applied to test the differences between two or more groups. A Bonferroni correction was applied to multiple comparisons. For both univariate and multivariate linear regression models, Ab42 and Ab42/Ab40 values were transformed into a natural logarithmic scale (ln) to obtain a normal data distribution.
Using univariate linear regression models, we tested the effect of preanalytical variables on CSF biomarker results.
For multivariate linear regression models, we used the Ab score as a dependent variable and the ln(Ab42) or the ln(Ab42/Ab40) as an independent variable. We tested by univariate models the possible contribution of each demographic variable in predicting the Ab score and then added to the multivariate model only those with significant associations, using a stepwise approach with the application of the Likelihood ratio test at each step. We considered as possible covariates the age, sex, disease duration, interval between CSF collection and death, ApoE e4 allele (presence or absence), prion disease (presence or absence), and AD tau score. Finally, we applied Bayesian information criteria (BIC) 34 to select the best performing model in the comparison between the one with ln(Ab42) and the one with ln(Ab42/Ab40).
ROC analyses were obtained to compare the diagnostic value of Ab42 and Ab42/Ab40 ratio. The optimal cut-off value for biomarkers was chosen using the maximized Youden index. The Delong test 35 was used to compare the areas under the curve (AUC) of Ab42 and Ab42/ Ab40 ratio. Differences were considered statistically significant at P < 0.05.
Results
Demographics, CSF biomarker values, and AD-related neuropathology scores (Table 1) Patients with AD or AD/DLB mixed pathology showed significantly lower Ab42 levels than those with prion disease (P < 0.001), inflammatory diseases (P = 0.013), and other RPDs (P = 0.001) ( Table 2) . Conversely, the levels of Ab42 did not vary significantly among non-AD diagnostic groups (e.g., prion disease, inflammatory diseases and other RPDs). There were also no significant differences in the CSF levels of Ab40 between AD or AD/DLB, prion disease, inflammatory diseases, and the other RPD groups. The results of CSF Ab42 and Ab40 analysis in patients with and without CAA and the effects of preanalytical variables are shown in Appendix S1. 
Correlations between CSF biomarkers and amyloid-beta pathology
In the total cohort, the Ab score showed a better correlation with ln(Ab42/Ab40) (R 2 = 0.506, b = À0.713, P < 0.001) than with ln(Ab42) (R 2 = 0.206, b = À0.458, P < 0.001) ( Table 3 and Figure 2) . Accordingly, the model including ln(Ab42/Ab40) yielded a lower BIC value (1096.1) than that including ln(Ab42) (1196.3), suggesting that ln(Ab42/Ab40) is a better explanatory variable. We found similar associations [ln(Ab42): R 2 = 0.547, b = À0.239, P < 0.001; ln(Ab42/Ab40): R 2 = 0.634, b = À0.460, P < 0.001] and a lower BIC value for the model with ln(Ab42/Ab40) (1031.2) than that with ln (Ab42) (1075.4), after accounting for covariates by multivariate regression analysis (Table 3) .
When we considered only the cases with Ab42 levels lower than ≤495 pg/mL (n = 98), the difference of the correlation coefficients between Ab score and ln(Ab42/Ab40) (R 2 = 0.591, b = À0.772, P < 0.001) and Ab score and ln (Ab42) (R 2 = 0.040, b = À0.224, P = 0.026) increased further. The latter result was confirmed after adjusting for covariates [ln(Ab42): R 2 = 0.536, b = À0.036, P < 0.001; ln(Ab42/Ab40): R 2 = 0.686, b = À0.507, P < 0.001]. In both analyses, either not-adjusted or adjusted for covariates, the BIC values of the models with ln(Ab42/Ab40) were lower (513.6 and 486.3, respectively) than those of the models with ln(Ab42) (597.2 and 523.6). Optimal multivariate linear regression models using the Ab postmortem pathology score as the dependent variable and either CSF ln(Ab42) levels or ln(Ab42/Ab40) as independent variable after adjusting for covariates (age at LP, AD tau score, presence of prion disease, presence of ApoE e4). Ab, amyloid beta; AD, Alzheimer's disease; CI, interval of confidence; ln, natural logarithm; LP, lumbar puncture; SE, standard error; y, years. 
Diagnostic accuracy of CSF amyloid-betarelated biomarkers
Based on our intralaboratory Ab42 cut-off value, we extended the assessment of the relative diagnostic accuracy of each amyloid-related biomarker to the group of patients with Ab42 levels lower than 495 pg/mL. In this group and in the total cohort, we performed ROC analyses according to: (1) the presence of Thal's phase 3-5 versus 0-2, (2) the presence or absence of AD pathology as assessed by the ABC score (AD+ vs. AD-), and (3) the presence of a intermediate-high versus low-not AD pathology.
In the total cohort (N = 211), the Ab42/Ab40 ratio was superior to Ab42 in the distinction between cases with or without AD pathology (AUC 0.818 AE 0.028 vs. 0.643 AE 0.039). As expected, the analyses (1) and (3) yielded similar results (Table 4 ). Most significantly, using cut-off values of 405 pg/mL for Ab42 and 0.810 for Ab42/ Ab40, ratio the analyses yielded 75.7% or 87.0% sensitivity and 76.5% or 88.2% specificity, respectively, in the distinction between cases with an intermediate-high level of AD pathology and those with low level and no AD pathology. AUC, sensitivity, and specificity values for all analyses are reported in Table 4 . For every ROC analysis, the AUC of Ab42/Ab40 ratio was significantly higher than that of Ab42 at Delong test.
When we restricted the analysis to patients with Ab42 levels lower than 495 pg/mL, we observed a significant increase in the accuracy of Ab42/Ab40 ratio (AUC 0.939 AE 0.022) in the prediction of Thal's phases (3-5 vs. 0-2), whereas the accuracy of Ab42 decreased (AUC Table 4 . ROC analyses in the total cohort. 0.613 AE 0.057) (P < 0.001). The same trend, with the ratio showing significantly higher values (AUC 0.888 AE 0.032; 0.869 AE 0.036) in comparison to Ab42 (AUC 0.518 AE 0.064; 0.650 AE 0.058) (P < 0.001 and P = 0.002), was observed by considering the AD pathology score (analyses 2 and 3, respectively). Details about the distribution of AD pathological changes in the patient cohort according to given ranges of values of CSF Ab42/Ab40 ratio are provided in Figure 3 .
Discussion
The results of the present study demonstrate that, in patients with RPD of various etiology, the measurement of Ab42/Ab40 ratio in CSF samples taken shortly before death predicts better than CSF Ab42 levels the burden of Ab brain deposits. The assessment of diagnostic accuracy in pathologically verified case series represents the gold standard for biomarker validation. Nevertheless, only a few studies have consistently correlated Ab42 values in vivo with postmortem Ab pathology, 7, 8 while none has, to date, specifically considered the predictive value of the Ab42/Ab40 ratio on Ab pathology. Moreover, such studies are hampered by the long latency between the in vivo and postmortem assessments, which are especially relevant considering the current need to validate the diagnostic biomarkers for AD and other neurodegenerative diseases in the prodromal or even preclinical stage. 10, 36, 37 Brains affected by CJD and other RPDs provide the unique opportunity to correlate the CSF findings with the postmortem neuropathology within a short time interval. 13 Moreover, by including patients who were virtually asymptomatic before the onset of the RPD, such a series represents well the population in which the accuracy of in vivo markers for AD needs to be validated the most (i.e., elderly asymptomatic patients with various degree of AD pathology). 10, 36, 37 According to our data, the Ab42/Ab40 ratio performs significantly better than Ab42 alone in predicting the whole spectrum of AD pathological changes, not only the burden of Ab deposits. However, the added value of the ratio appears to decrease with increasing severity of AD pathology, being highest in cases with low or even absent Ab deposition, which especially underlines the importance of the Ab42/Ab40 ratio in the identification of the "false positive" samples with low Ab42 reflecting causes other than the Ab-related pathology. These confounders are well known and include not only preanalytical factors, such as the interval between collection and freezing, sample exposure to storage surfaces, and assay measurement variation, 10, 11, 38 and comorbidities affecting Ab metabolism, but also the individual variability in CSF Ab42 production. Indeed, evidence indicates that CSF Ab peptide concentration varies between individuals and some subjects may be constitutively low Ab42 producers. 16 Moreover, pathological changes other than Ab deposition such as synaptic loss might contribute to the reduction of Ab levels, including Ab42. 39 Accordingly, in the clinical setting, the occurrence of indeterminate results, revealing abnormal Ab42 levels and normal t-tau and p-tau, is a significant problem limiting the diagnostic accuracy of CSF biomarkers in suspected AD cases. 6, 23, 24 In this respect, the use of t-tau/Ab42 or p-tau/Ab42 ratios has shown a better diagnostic performance in comparison to the single biomarker determination, 10, 40 and with an overall accuracy comparable to that of Ab42/Ab40 ratio. 41, 42 However, given that CSF tau and Ab reflect distinct pathological processes which have different importance regarding both specificity and time of appearance, the use of a ratio targeted to a single proteinopathy appears more rationale and might even be more accurate in preclinical AD. Indeed, according to the prevailing amyloid hypothesis, Ab aggregation represents the primary and most specific pathological event in AD since tau deposition may occur secondarily to many other pathologies. Accordingly, AD biomarkers are increasingly being distinct in Ab deposition, tau pathology, and neurodegeneration, following the A/T/N classification. 36, 43 Consequently, the identification and implementation of the biomarkers with the highest specificity and accuracy in measuring the degree of Ab pathology should be the primary goal, 36 especially in the earlier disease stages when tau pathology is not widespread yet. The results of a recent study showing that the accuracy of [18F]flortaucipir PET in the discrimination between AD and other neurodegenerative disorders is lower at the prodromal stage of AD support this conclusion. 44 In this regard, the Ab42/Ab40 ratio is emerging as the best current candidate CSF biomarker for Ab pathology since it minimizes biases linked to preanalytical and analytical factors, and the inter-individual variability of Ab production. 18, 25, 26 In this context, our results do not propose a novel marker, but rather provide extensive neuropathological data, from a large patient cohort, in support of the added value of the Ab42/Ab40 ratio in the diagnostic AD assessment. The results obtained recommend the use of the Ab42/Ab40 ratio in the clinical evaluation of AD pathology using CSF biomarkers, especially in cases with an "indeterminate" CSF profile, characterized by normal t-tau and ptau and low Ab42 levels.
Limitations of the present study mainly concern the inclusion of cases with CJD and other causes of RPD such as encephalitis, in which previous studies documented a reduction of mean CSF Ab42 levels in comparison to normal subjects. 45, 46 However, in our cohort, we found comparable levels of CSF Ab42 among the non-AD diagnostic groups. Additionally, we obtained the same correlation between amyloid CSF biomarkers and Ab score after accounting for the presence of prion disease, which indicates that the findings are not only related to a CJD-specific effect. Finally, the influence of copathologies on Ab levels in the CSF has also a significant impact in clinical practice given that mixed brain pathologies frequently affect the elderly population. 47 While the unbalanced cohort, mainly represented by CJD cases, is a recognized limit of our study, the focus on CJD and other RPDs provided the unique opportunity to analyze CSF data on samples collected, on average, only a few months before death and in several brains with a degree of Ab pathology corresponding to presymptomatic AD.
We choose not to include CSF t-tau and p-tau data in our analyses because of the high proportion of CJD cases in the cohort. Indeed, CSF t-tau and, at least in some subtypes, p-tau levels may increase in CJD independently from the coexisting AD pathology. Moreover, previous data from our group demonstrated that in typical sCJD (e.g., MM1 subtype), in which p-tau CSF levels are not significantly elevated, p-tau fails to consistently discriminate between patients with or without age-or AD-related neurofibrillary pathology when tau deposition is limited to the medial temporal lobe (Braak stages I-III), the stages most commonly associated with early asymptomatic AD. 13 In conclusion, the present data provide strong support for the use of CSF Ab42/Ab40 ratio as a biomarker for Ab-related pathology (A category in the A/T/N scheme) in clinical practice and its introduction in the research diagnostic criteria for AD.
